News & Media

Admedus attracts keen interest from surgeons at symposium

11, July, 2017

Posted In: Featured, Blog

Professor Leon Neethling recently attended the 53rd Annual Meeting of the Japanese Society of Paediatric Cardiology and Cardiac Surgery, in Hamamatsu, where he presented at a lunch symposium to more than 180 congenital surgeons from Japan, Vietnam, Philippines, Malaysia, Taiwan and Korea about our ADAPT products as part of the 13th Japan-China-Korea Paediatric Heart Forum.

> Read more

Admedus Ltd readies commercial CardioCel® 3D launch

11, July, 2017

Posted In: Featured, In the media

Proactive Investors takes a look at our plans for CardioCel 3D. Read their latest article here.

> Read more

Admedus CEO Wayne Paterson interview with Proactive Investors

4, July, 2017

Posted In: Featured, In the media, Videos

Our CEO Wayne Paterson recently shared his thoughts and vision for Admedus in this interview with Proactive Investors. Watch it now.

> Read more

How to regenerate a regenerative company: CEO talks to MassDevice

4, July, 2017

Posted In: Featured, In the media

Our CEO Wayne Paterson was recently interviewed by MassDevice about the progress Admedus is making. Read the story here.  

> Read more

Admedus welcomes new Chief Operating Officer

9, June, 2017

Posted In: Featured

Admedus welcomes David St. Denis as our new Chief Operating Officer. Read the full Company announcement here.

> Read more

Admedus HSV 2 Phase IIa Results – May 2017

8, May, 2017

Posted In: Videos, Uncategorized

> Watch the video

Admedus Investor Presentation – February 2017

28, February, 2017

Posted In: Videos, Uncategorized

> Read more

CardioCel: 8 years on and still free from calcification

23, August, 2016

Posted In: Blog, Uncategorized

CardioCel® is proving to be one of the biggest game changers in the congenital heart defect repairs and reconstructions space, offering significant long-term benefits to patients. While other tissue patches can calcify up to 18 months post implantation in paediatric patients, the latest follow up data released by Admedus shows no evidence of calcification using […]

> Read more

Long-term CardioCel study shows no evidence of calcification after 8 years

22, August, 2016

Posted In: Uncategorized

Admedus Limited (ASX: AHZ) has today announced positive long-term data from its Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel. All patients continue to progress well, with no sign of calcification after 8 years or need for repeat procedures. Read the full Company announcement here.

> Read more

Long-term study indicates no calcification with CardioCel after eight years

22, August, 2016

Posted In: In the media, Uncategorized

Long-term data from a Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel shows that all patients continue to progress well, with no sign of calcification or need for repeat procedures.

> Read more